Voclosporin Withdrawn From Approval for Uveitis in EU Medscape The immunosuppressant was intended for the treatment of chronic noninfectious uveitis involving the posterior or intermediate segments of the eyes, with a high degree of inflammation, in patients for whom corticosteroids are inappropriate, ... EMA: Lux Biosciences Withdraws Marketing Authorization Application For Luveniq |
